Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Senseonics registered for an initial public offering worth up to $51.8 million as it gear up to get its Eversense implantable continuous glucose monitor on the market.
Germantown, Md.-based Senseonics said the Eversense system is designed to continuously monitor a patient’s glucose levels for up to 90 days. It uses a subcutaneous sensor and an external, removable smart transmitter linked to a mobile app designed to deliver real-time glucose levels, alerts and other data. Read more
Pfizer is reportedly mulling a sale of the infusion pump business it acquired along with Hospira last year, aiming to focus on its core branded pharmaceuticals business.
Hospira makes generic versions of injectable drugs used in hospitals, pumps to deliver them and also sells biosimilars or copies of biotech drugs. New York City-based Pfizer closed the $15 billion acquisition last September. Read more
Share prices for Hansen Medical surged in pre-market trading this morning after the beleaguered robot-assisted surgery company said it’s seeking the proverbial “strategic alternatives.”
Mountain View, Calif.-based Hansen, which makes the Magellan and Sensei surgical robots, said it formed a special committee of its independent board members to evaluate potential moves, including a sale of the company and tapped Perella Weinberg Partners as a financial advisor. Read more